Systemic lupus erythematosus (SLE) is an autoimmune disease with protean manifestations
that predominantly affects young women. Certain ethnic groups are more vulnerable than …

SLE is a chronic autoimmune rheumatic disorder of high heterogeneity in clinical
presentation, treatment response and prognosis. Long-term outcomes in SLE have been …

Objectives To quantify global, regional and country-specific estimates of epidemiology of
systemic lupus erythematosus (SLE). Methods Four databases were systematically …

Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …

Background Baricitinib is an oral selective inhibitor of Janus kinase 1 and 2 approved for the
treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. In a 24-week phase …

Background: B-cell depletion with rituximab is commonly used for patients with systemic
lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable …

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease that causes
damage to multiple organ systems. Despite decades of research and available murine …

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
characterized by organ damage, flare-remission pattern, and increased mortality when …

Obtaining an updated view of the epidemiology, risk factors, and prognosis of systemic lupus
erythematosus (SLE) is pivotal to our understanding of the disease burden. Recent …